204 related articles for article (PubMed ID: 16758298)
1. Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis.
Moschos SJ; Mo YY
J Mol Histol; 2006 Sep; 37(5-7):309-19. PubMed ID: 16758298
[TBL] [Abstract][Full Text] [Related]
2. Ubc9- and mms21-mediated sumoylation counteracts recombinogenic events at damaged replication forks.
Branzei D; Sollier J; Liberi G; Zhao X; Maeda D; Seki M; Enomoto T; Ohta K; Foiani M
Cell; 2006 Nov; 127(3):509-22. PubMed ID: 17081974
[TBL] [Abstract][Full Text] [Related]
3. ATPase-dependent control of the Mms21 SUMO ligase during DNA repair.
Bermúdez-López M; Pociño-Merino I; Sánchez H; Bueno A; Guasch C; Almedawar S; Bru-Virgili S; Garí E; Wyman C; Reverter D; Colomina N; Torres-Rosell J
PLoS Biol; 2015 Mar; 13(3):e1002089. PubMed ID: 25764370
[TBL] [Abstract][Full Text] [Related]
4. Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53.
Lin JY; Ohshima T; Shimotohno K
FEBS Lett; 2004 Aug; 573(1-3):15-8. PubMed ID: 15327968
[TBL] [Abstract][Full Text] [Related]
5. SIM-dependent enhancement of substrate-specific SUMOylation by a ubiquitin ligase in vitro.
Parker JL; Ulrich HD
Biochem J; 2014 Feb; 457(3):435-40. PubMed ID: 24224485
[TBL] [Abstract][Full Text] [Related]
6. Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage.
Shima H; Suzuki H; Sun J; Kono K; Shi L; Kinomura A; Horikoshi Y; Ikura T; Ikura M; Kanaar R; Igarashi K; Saitoh H; Kurumizaka H; Tashiro S
J Cell Sci; 2013 Nov; 126(Pt 22):5284-92. PubMed ID: 24046452
[TBL] [Abstract][Full Text] [Related]
7. Smt3/SUMO and Ubc9 are required for efficient APC/C-mediated proteolysis in budding yeast.
Dieckhoff P; Bolte M; Sancak Y; Braus GH; Irniger S
Mol Microbiol; 2004 Mar; 51(5):1375-87. PubMed ID: 14982631
[TBL] [Abstract][Full Text] [Related]
8. Purification and activity assays for Ubc9, the ubiquitin-conjugating enzyme for the small ubiquitin-like modifier SUMO.
Yunus AA; Lima CD
Methods Enzymol; 2005; 398():74-87. PubMed ID: 16275321
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
Xu J; Watkins T; Reddy A; Reddy ES; Rao VN
Int J Oncol; 2009 Apr; 34(4):939-49. PubMed ID: 19287951
[TBL] [Abstract][Full Text] [Related]
10. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation.
Jakobs A; Koehnke J; Himstedt F; Funk M; Korn B; Gaestel M; Niedenthal R
Nat Methods; 2007 Mar; 4(3):245-50. PubMed ID: 17277783
[TBL] [Abstract][Full Text] [Related]
11. Covalent conjugation of the equine infectious anemia virus Gag with SUMO.
Wang J; Wen S; Zhao R; Qi J; Liu Z; Li W; An J; Wood C; Wang Y
Biochem Biophys Res Commun; 2017 May; 486(3):712-719. PubMed ID: 28342872
[TBL] [Abstract][Full Text] [Related]
12. S. cerevisiae Mre11 recruits conjugated SUMO moieties to facilitate the assembly and function of the Mre11-Rad50-Xrs2 complex.
Chen YJ; Chuang YC; Chuang CN; Cheng YH; Chang CR; Leng CH; Wang TF
Nucleic Acids Res; 2016 Mar; 44(5):2199-213. PubMed ID: 26743002
[TBL] [Abstract][Full Text] [Related]
13. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
14. SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase.
Pfander B; Moldovan GL; Sacher M; Hoege C; Jentsch S
Nature; 2005 Jul; 436(7049):428-33. PubMed ID: 15931174
[TBL] [Abstract][Full Text] [Related]
15. Identification of SUMO modification sites in the base excision repair protein, Ntg1.
Swartzlander DB; McPherson AJ; Powers HR; Limpose KL; Kuiper EG; Degtyareva NP; Corbett AH; Doetsch PW
DNA Repair (Amst); 2016 Dec; 48():51-62. PubMed ID: 27839712
[TBL] [Abstract][Full Text] [Related]
16. RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.
Yan J; Yang XP; Kim YS; Joo JH; Jetten AM
Biochem Biophys Res Commun; 2007 Oct; 362(1):132-138. PubMed ID: 17698038
[TBL] [Abstract][Full Text] [Related]
17. Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae.
Klug H; Xaver M; Chaugule VK; Koidl S; Mittler G; Klein F; Pichler A
Mol Cell; 2013 Jun; 50(5):625-36. PubMed ID: 23644018
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk.
Dünnebier T; Bermejo JL; Haas S; Fischer HP; Pierl CB; Justenhoven C; Brauch H; Baisch C; Gilbert M; Harth V; Spickenheuer A; Rabstein S; Pesch B; Brüning T; Ko YD; Hamann U
Breast Cancer Res Treat; 2010 May; 121(1):185-94. PubMed ID: 19760037
[TBL] [Abstract][Full Text] [Related]
19. The RAD6 pathway: control of DNA damage bypass and mutagenesis by ubiquitin and SUMO.
Ulrich HD
Chembiochem; 2005 Oct; 6(10):1735-43. PubMed ID: 16142820
[No Abstract] [Full Text] [Related]
20. Targeting Ubc9 for cancer therapy.
Mo YY; Moschos SJ
Expert Opin Ther Targets; 2005 Dec; 9(6):1203-16. PubMed ID: 16300471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
